1. Scrip
  2. >>Business

Galapagos Enters Cancer Field With CellPoint Buy

 
• By Jessica Merrill

Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.

shopping bags
Galapagos is shopping for new assets • Source: Shutterstock

Who: Galapagos NV/CellPoint B.V.

What: Galapagos is buying the Dutch cell therapy company CellPoint, which is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business